Literature DB >> 1923510

Increase in specific DNA binding by carboxyl truncation suggests a mechanism for activation of Myb.

R G Ramsay1, S Ishii, T J Gonda.   

Abstract

Oncogenic forms of the c-myb protein (Myb) often exhibit amino-terminal and/or carboxyl-terminal truncations. When the transcriptional activity of these proteins was examined it was found that carboxyl-truncated Myb is more effective as a transcriptional activator than full-length or amino-truncated Myb. In order to determine the effect of such truncations on sequence-specific DNA binding, we synthesized murine Myb in vitro and assessed DNA binding by using a mobility-shift assay. Compared with the full-length protein no difference in binding was observed following deletion of the amino terminus, despite the removal of much of the first repeat of the DNA-binding domain. However, the specific DNA-binding capacity of carboxyl-truncated Myb was 4-6 times greater than that of the full-length protein; moreover, DNA binding was independent of a 'leucine zipper' motif present in Myb. These observations suggest that the increased transforming and transactivating potential of carboxyl-truncated Myb is due, at least in part, to increased sequence-specific DNA binding.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1923510

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  Transcriptional activation of a retrovirus enhancer by CBF (AML1) requires a second factor: evidence for cooperativity with c-Myb.

Authors:  A L Zaiman; J Lenz
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

2.  Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules.

Authors:  V Facchinetti; L Loffarelli; S Schreek; M Oelgeschläger; B Lüscher; M Introna; J Golay
Journal:  Biochem J       Date:  1997-06-15       Impact factor: 3.857

3.  Molecular cloning reveals that the p160 Myb-binding protein is a novel, predominantly nucleolar protein which may play a role in transactivation by Myb.

Authors:  F J Tavner; R Simpson; S Tashiro; D Favier; N A Jenkins; D J Gilbert; N G Copeland; E M Macmillan; J Lutwyche; R A Keough; S Ishii; T J Gonda
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

4.  Extension of the DNA binding consensus of the chicken c-Myb and v-Myb proteins.

Authors:  K Weston
Journal:  Nucleic Acids Res       Date:  1992-06-25       Impact factor: 16.971

5.  Only the DNA binding and transactivation domains of c-Myb are required to block terminal differentiation of murine erythroleukemia cells.

Authors:  A E Cuddihy; L A Brents; N Aziz; T P Bender; W M Kuehl
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

6.  Suppressor screen in Mpl-/- mice: c-Myb mutation causes supraphysiological production of platelets in the absence of thrombopoietin signaling.

Authors:  Marina R Carpinelli; Douglas J Hilton; Donald Metcalf; Jennifer L Antonchuk; Craig D Hyland; Sandra L Mifsud; Ladina Di Rago; Adrienne A Hilton; Tracy A Willson; Andrew W Roberts; Robert G Ramsay; Nicos A Nicola; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-07       Impact factor: 11.205

7.  Transcription regulation by murine B-myb is distinct from that by c-myb.

Authors:  R J Watson; C Robinson; E W Lam
Journal:  Nucleic Acids Res       Date:  1993-01-25       Impact factor: 16.971

8.  Overexpression of C-terminally but not N-terminally truncated Myb induces fibrosarcomas: a novel nonhematopoietic target cell for the myb oncogene.

Authors:  R D Press; E P Reddy; D L Ewert
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

9.  Oncogenic truncation of the first repeat of c-Myb decreases DNA binding in vitro and in vivo.

Authors:  P W Dini; J S Lipsick
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Casein kinase II phosphorylation site mutations in c-Myb affect DNA binding and transcriptional cooperativity with NF-M.

Authors:  M Oelgeschläger; J Krieg; J M Lüscher-Firzlaff; B Lüscher
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.